RE:New Press Release - Spectral Medical Announces Investor Update Conference CallNotice that in the "About Spectral" of this Press Release they no longer say one word about Dialco, DIMI or SAMI, iDialco..
But, the company still contends the loss of these valuable assets are not "Material Information".
Maybe today they will take questions re: sketchy leadership..
Here is their "About Spectral" as recently as November 2022.
"Spectral, through its wholly owned subsidiary, Dialco Medical Inc., is also commercializing a new set of proprietary platforms addressing renal replacement therapy (RRT) across the dialysis spectrum. SAMI is targeting the acute RRT market, while DIMI is targeting the chronic RRT market. Dialco is currently pursuing regulatory approval for U.S. in-home use of DIMI, which is based on the same RRT platform as SAMI, but will be intended for home hemodialysis use. DIMI recently received its FDA 510k clearance for use in hospital and clinical settings, and obtained its Health Canada license for use within Canadian hospitals, clinics and in home."